Jane Street’s Perspective Therapeutics CATX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-263,995
Closed -$1.12M 11676
2025
Q4
$726K Sell
263,995
-65,678
-20% -$187K ﹤0.01% 6872
2025
Q3
$1.13M Buy
+329,673
New +$1.2M ﹤0.01% 6053
2025
Q2
Sell
-61,021
Closed -$130K 9718
2025
Q1
$130K Buy
61,021
+17,697
+41% +$53.1K ﹤0.01% 8688
2024
Q4
$138K Buy
43,324
+18,068
+72% +$148K ﹤0.01% 8615
2024
Q3
$337K Sell
25,256
-53,404
-68% -$710K ﹤0.01% 7833
2024
Q2
$784K Buy
78,660
+71,954
+1,073% +$1.04M ﹤0.01% 6242
2024
Q1
$79.8K Buy
6,706
+5,405
+415% +$46.1K ﹤0.01% 8611
2023
Q4
$5.23K Sell
1,301
-13,379
-91% -$37.7K ﹤0.01% 9013
2023
Q3
$40.2K Buy
14,680
+13,458
+1,101% +$62.8K ﹤0.01% 8197
2023
Q2
$8.16K Buy
+1,222
New +$7.42K ﹤0.01% 8457
2023
Q1
Sell
-4,944
Closed -$12.2K 9089
2022
Q4
$12.2K Buy
+4,944
New +$16.3K ﹤0.01% 8722
2022
Q3
Sell
-2,077
Closed -$6K 9743
2022
Q2
$6K Buy
2,077
+874
+73% +$2.67K ﹤0.01% 9388
2022
Q1
$4K Sell
1,203
-3,032
-72% -$11.1K ﹤0.01% 10140
2021
Q4
$16K Buy
+4,235
New +$22.6K ﹤0.01% 9838
2021
Q1
Sell
-2,472
Closed -$11K 9113
2020
Q4
$11K Buy
+2,472
New +$10.9K ﹤0.01% 7386

Other funds holding CATX

Jane Street's CATX Position: Q1 2026 in Review

Jane Street sold out of Perspective Therapeutics (CATX) in Q1 2026, closing a stake of 263,995 shares — an estimated $1.12M sold.

Jane Street first reported a position in CATX in Q4 2020 and held it in 15 quarters. The position peaked at $1.13M in Q3 2025. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Jane Street reported no remaining Perspective Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 263,995 Perspective Therapeutics shares in Q1 2026, an estimated $1.12M.
  • Jane Street first reported a position in Perspective Therapeutics in Q4 2020 and held it in 15 quarters.
  • Jane Street's Perspective Therapeutics position peaked at $1.13M in Q3 2025.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.